Triggers | Major cellular drivers | Major molecular drivers | Related clinical features | |
Type 2 asthma | ||||
Allergic eosinophilic | Allergens | Airway epithelial cells, Th2 lymphocytes, eosinophils | IL-25, IL-33, TSLP, IL-4, IL-5, IL-13, IgE | More common in children Good response to corticosteroids Reversible airway obstruction Associated with upper airway comorbidities |
Nonallergic eosinophilic | Pollutants, microbes, glycolipids | Airway epithelial cells, ILC2s, eosinophils | IL-25, IL-33, TSLP, PGD2 | Less common in children (late-onset) Significant AHR Relatively insensitive to corticosteroids No increased atopy |
Non-type 2 asthma | ||||
Paucigranulocytic | Environmental factors (cigarette smoke, allergens, contractile agonists) | ASM dysfunction; no cellular inflammation | High level of oxidative stress (mechanisms not known) | High AHR Insensitivity to corticosteroids |
Neutrophilic | Infections | Th17 lymphocytes, neutrophils | IL-17, IL-21, IL-22 | Bacterial airway colonisation Poor response to corticosteroids Severe airway obstruction |
Th: T-helper cell; IL: interleukin; TSLP: thymic stromal lymphopoietin; IgE: immunoglobulin E; ILC2s: innate lymphoid cells type 2; PGD2: prostaglandin D2; AHR: airway hyperresponsiveness; ASM: airway smooth muscle cells.